Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FSQP2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $15,792.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The delivery order, awarded on December 11, 2025, with an ultimate completion date of January 5, 2026, carries no set-aside designation, indicating the award was made through unrestricted federal procurement competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency designated as SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as a critical supplier within the military pharmaceutical supply chain, with its established performance across numerous delivery orders spanning diverse therapeutic categories. The company's selection as a prime vendor contractor under PPV-G GEN V positions it to serve the recurring pharmaceutical needs of DoD medical facilities globally, with the IDC providing a ceiling value of $499,999,999 through December 31, 2036. This specific delivery order for Xolair, an immunosuppressant biologic agent, reflects the company's capability to fulfill specialized pharmaceutical requirements essential to military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FSQP2?
SPE2DR26FSQP2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FSQP2 worth?
The government has obligated $15,792 on SPE2DR26FSQP2.
Is contract SPE2DR26FSQP2 an order under another contract?
Yes. SPE2DR26FSQP2 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQP2 competed?
The extent of competition for SPE2DR26FSQP2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award